Skip to main content
Top
Published in: Breast Cancer Research and Treatment 1/2009

01-09-2009 | Letter to the Editor

Sustained lower rates of breast cancer in the United States

Authors: Kathleen A. Cronin, Peter M. Ravdin, Brenda K. Edwards

Published in: Breast Cancer Research and Treatment | Issue 1/2009

Login to get access

Excerpt

We have previously reported that, a sharp decrease in breast cancer incidence rates had occurred in 2003 among women ≥50 years of age in the United States [1]. This decrease seemed temporally related to a decrease in the use of hormone replacement therapy. In this update (Fig. 1) we report that, this decrease has been maintained into 2005. Comparing incidence from years 2000 through 2002 to years 2003 through 2005 significant decreases of 12.0% (se 0.8) and 7.8% (se 1.0) are seen for women 50–69 and >70 years of age, respectively. No significant decrease occurred in women less than 50. This reanalysis using the most recently released data from SEER [2] shows that, the decrease occurred primarily in ER positive breast cancers, with the rate of ER positive breast cancer in women 50–69 years of age decreasing 14.5% and ER negative breast cancers decreasing 2.1%.
Literature
1.
go back to reference Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, Edwards BK, Berry DA (2007) The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356(16):1670–1674. doi:10.1056/NEJMsr070105 PubMedCrossRef Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, Edwards BK, Berry DA (2007) The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356(16):1670–1674. doi:10.​1056/​NEJMsr070105 PubMedCrossRef
2.
go back to reference Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence—SEER 9 Regs Limited-Use, Nov 2007 Sub (1973–2005) released April 2008, based on the November 2007 submission Surveillance, Epidemiology, and End Results (SEER) Program (www.​seer.​cancer.​gov) SEER*Stat Database: Incidence—SEER 9 Regs Limited-Use, Nov 2007 Sub (1973–2005) released April 2008, based on the November 2007 submission
3.
go back to reference Glass AG, Lacey JV Jr, Carreon JD, Hoover RN (2007) Breast cancer incidence, 1980–2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 99:1152–1161. doi:10.1093/jnci/djm059 PubMedCrossRef Glass AG, Lacey JV Jr, Carreon JD, Hoover RN (2007) Breast cancer incidence, 1980–2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 99:1152–1161. doi:10.​1093/​jnci/​djm059 PubMedCrossRef
4.
go back to reference Canfell K, Banks E, Moa AM, Beral V (2008) Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. Med J Aust 188(11):641–644PubMed Canfell K, Banks E, Moa AM, Beral V (2008) Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. Med J Aust 188(11):641–644PubMed
Metadata
Title
Sustained lower rates of breast cancer in the United States
Authors
Kathleen A. Cronin
Peter M. Ravdin
Brenda K. Edwards
Publication date
01-09-2009
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-008-0226-8

Other articles of this Issue 1/2009

Breast Cancer Research and Treatment 1/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine